13% of women will develop breast cancer in their life, meaning that 1 in 8 women are at risk for developing breast cancer. This risk is significantly increased in women carrying germline mutations in BRCA1 and BRCA2, where up to 60% of carriers will develop breast cancer in their lifetime. Since BRCA is involved in DNA repair and telomere maintenance, telomere length is a potential biomarker of breast cancer risk. Breast cancer carriers have significantly shorter telomeres than noncarriers. In addition, decreased telomere length is associated with aging and disease. My project investigates the relationship between BRCA mutations and telomere length. By utilizing the Monochrome Multiplex Quantitative PCR Assay, I will quantify telomere length in BRCA mutation carriers and noncarriers. This research identifies if telomere length is a biomarker for breast cancer risk.